Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.2790
+0.0035 (1.27%)
At close: Aug 12, 2025, 4:00 PM
0.2799
+0.0009 (0.32%)
After-hours: Aug 12, 2025, 7:52 PM EDT
Lumos Pharma Employees
Carisma Therapeutics had 46 employees as of December 31, 2024. The number of employees decreased by 61 or -57.01% compared to the previous year.
Employees
46
Change (1Y)
-61
Growth (1Y)
-57.01%
Revenue / Employee
$234,065
Profits / Employee
-$1,073,413
Market Cap
11.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46 | -61 | -57.01% |
| Dec 31, 2023 | 107 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CARM News
- 4 months ago - Carisma Therapeutics Provides Corporate Updates - PRNewsWire
- 6 months ago - Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - PRNewsWire
- 6 months ago - Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 8 months ago - Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline - PRNewsWire
- 9 months ago - Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PRNewsWire
- 9 months ago - Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PRNewsWire
- 9 months ago - Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - PRNewsWire
- 9 months ago - Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire